Five patients with non-melanoma skin cancer were treated with immune checkpoint inhibitors, two with locally advanced squamous cell carcinoma (cemiplimab, anti-PD1), and three with metastatic Merkel cell carcinoma (avelumab, anti-PD-L1). Here, PDCD1 is linked to squamous cell carcinoma.